RENVISTOBART

also known as BMS-986207

Developed for: non-small cell lung carcinoma · plasma cell myeloma · refractory plasma cell neoplasm
Investigated by: Bristol-Myers Squibb · Beth Israel Deaconess Medical Center · Dana-Farber Cancer Institute · Emory University · Hackensack Meridian Health · Icahn School of Medicine at Mount Sinai
+7 more
· Memorial Sloan Kettering Cancer Center · Multiple Myeloma Research Consortium · Ono Pharmaceutical Co., Ltd. · University of Michigan · University of Texas · Wake Forest University Health Sciences · Washington University School of Medicine

20172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/22 trials
Phase 1/2	NCT04150965	Jul 2020 → Aug 2024	plasma cell myeloma, refractory plasma cell neoplasm	Multiple Myeloma Research Consortium	Terminated	No outcome recorded
Phase 1/2	NCT02913313	Nov 2016 → Jan 2024	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT05005273	Oct → Dec 2022	non-small cell lung carcinoma	Bristol-Myers Squibb	Completed	No outcome recorded
Comparator or background therapy1 trial
Phase 1/2	NCT04570839 Background	Aug 2020 → May 2024	endometrium neoplasm, head and neck cancer, ovarian cancer	Compugen Ltd	Completed	No outcome recorded

Every value below carries the sentence it was read from. 5 sources stand behind the page.

Field	Value	Cited text
Known as	RENVISTOBART	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297707 ↗
Known as	BMS-986207	“Anti-TIGIT (BMS-986207)” NCT04150965 ↗ 3 NCT05005273 ↗ NCT02913313 ↗ NCT04570839 ↗
Action	Inhibit	“BMS-986207 (an inhibitor of TIGIT)” NCT04570839 ↗
Modality	Monoclonal antibody	“Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors” NCT02913313 ↗
Route	Intravenous	“All study drugs will be administered IV every 4 weeks” NCT04570839 ↗
Target	TIGIT	“BMS-986207 (an inhibitor of TIGIT)” NCT04570839 ↗